Baseline characteristics of all enrolled patients
| All N=3482 | Non-CAD n=680 | CAD n=2802 | P value | |
| Male | 2543 (73.0) | 409 (60.1) | 2135 (76.2) | <0.001 |
| Age, years | 63 (56–70) | 62 (55–69) | 64 (56–70) | 0.001 |
| Hypertension | 2087 (59.9) | 366 (53.8) | 1721 (61.4) | <0.001 |
| Diabetes | 960 (27.6) | 111 (16.3) | 849 (30.3) | <0.001 |
| Smoking | 1592 (45.7) | 222 (32.6) | 1370 (48.9) | <0.001 |
| ALT, U/L | 23 (16–35) | 22 (15–32) | 24 (16–35) | <0.001 |
| AST, U/L | 23 (19–31) | 23 (19–28) | 24 (19–32) | 0.121 |
| TBIL, μmol/L | 12.75 (9.50–17.10) | 12.80 (9.50–16.80) | 12.70 (9.50–17.10) | 0.732 |
| ALB, g/L | 39.3 (37.0–42.0) | 39.6 (37.6–42.5) | 39.2 (36.9–41.8) | 0.023 |
| Creatinine, μmol/L | 64 (54–75) | 61 (52–73) | 64 (55–75) | 0.007 |
| Uric acid, μmol/L | 319 (271–373) | 311 (259–370) | 321 (274–373) | 0.068 |
| CK-MB, U/L | 12 (9–17) | 11 (8–15) | 12 (9–17) | 0.001 |
| Lg(NT-proBNP), pg/mL | 2.21 (1.82–2.72) | 2.00 (1.65–2.38) | 2.27 (1.88–2.78) | <0.001 |
| HbA1c, % | 5.7 (5.4–6.3) | 5.6 (5.3–6.0) | 5.8 (5.4–6.5) | 0.001 |
| Aspirin | 3372 (96.8) | 650 (95.6) | 2722 (97.1) | 0.037 |
| P2Y12 inhibitors | 3380 (97.1) | 649 (95.4) | 2731 (97.5) | 0.005 |
| Statins | 3401 (97.7) | 655 (96.3) | 2746 (98.0) | 0.009 |
| Gensini score | 29 (12–60) | 5 (2–7) | 40 (20–69) | <0.001 |
Data are presented as number (percentage) for categorical variables and as median (with 25th and 75th percentiles) for continuous variables.
ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; CAD, coronary artery disease; CK-MB, creatine kinase isoenzymes MB; HbA1c, glycated hemoglobin A1c; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; TBIL, total bilirubin.